Featured new tests in quarter two of 2026
Featured new tests
In the third quarter of 2026, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests, including:
- 1433E | 14-3-3 eta, Serum
- A potentially improved approach for the early identification of patients at risk for or with early and established rheumatoid arthritis (RA) in combination with specific autoantibody tests.
- This test is intended to be used as an aid in the early diagnosis of RA and management of the disease.
- ADNAP | Double-Stranded DNA (dsDNA) Antibodies Panel, IgG, Serum
- Useful for the evaluation of patients at-risk of systemic lupus for erythematosus (SLE) with abnormal antinuclear antibodies and management of affected individuals.
- Distinguishing SLE from other autoimmune diseases.
- COKEP | Cocaine and Metabolites, Plasma
- Useful for confirming drug exposure involving stimulants such as cocaine, benzoylecgonine, m-hydroxy-benzoylecgonine, and cocaethylene.
- INSAL | Insulin Analogs, Serum
- Detection and quantitation of native human insulin and insulin analogs in serum.
- Assessment of factitious hypoglycemia from misuse or surreptitious administration of insulin analogs.
- Monitoring treatment adherence of prescribed insulin therapy.
- Providing an alternative testing methodology for insulin measurements when immunoassay test results do not align with the clinical presentation and/or interference is suspected.
Learn more Unexplained hypoglycemia
- KDBAL | Karius Focus, Direct Ship, Bronchoalveolar Lavage
- Useful for the detection of microbial cell-free DNA from over 500 bacteria, fungi, parasites, and DNA viruses known to cause lung infections in bronchoalveolar lavage fluid.
Learn more Bronchoalveolar lavage fluid metagenomic testing
- MPHNS | Methylphenidate and Metabolite, Serum
- Useful for confirming drug exposure and monitoring serum concentrations of methylphenidate and ritalinic acid.
- PETNU | Phosphoethanolamine, Quantitative, Random, Urine
- Useful for the diagnosis of hypophosphatasia, especially in the setting of low alkaline phosphatase, bone fractures, and early tooth loss.
- Monitoring affected individuals on therapy.
- SXDBS | Sorbitol and Xylitol, Quantitative, Blood Spot
- Useful for the screening and treatment monitoring for sorbitol dehydrogenase deficiency-related neuropathy.
- Sorbitol dehydrogenase (SORD) deficiency is an autosomal recessive condition caused by biallelic variants in the SORD gene resulting in peripheral neuropathy, which may present clinically like Charcot-Marie-Tooth disease type 2 or distal hereditary motor neuropathy.
Visit our test catalog for more information on new or updated tests and testing algorithms.
